Bedingungsfaktoren psychopharmakologischer Behandlung bei leichter oder mittelgradiger Intelligenzminderung
Authors:
- 16 September 2016
- journal article
- research article
- Published by Springer Nature in Der Nervenarzt
- Vol. 88 (11) , 1273-1280
Abstract
No abstract availableKeywords
This publication has 22 references indexed in Scilit:
- Trends in the use of psychotropic drugs in people with intellectual disability in Taiwan: A nationwide outpatient service study, 1997–2007Research in Developmental Disabilities, 2014
- Prevalence of Psychotropic Drug Use in Adults with Intellectual Disability: Positive and Negative Findings from a Large Scale StudyJournal of Autism and Developmental Disorders, 2012
- Psychometric properties and norms of the German ABC-Community and PAS-ADD ChecklistResearch in Developmental Disabilities, 2011
- Die psychopharmakologische Therapie von Menschen mit geistiger Behinderung – Ein Vergleich der Jahre 1991 und 2005Psychiatrische Praxis, 2010
- Use of antipsychotic drugs in individuals with intellectual disability (ID) in the Netherlands: prevalence and reasons for prescriptionJournal of Intellectual Disability Research, 2010
- Psychotherapie bei Menschen mit IntelligenzminderungDer Nervenarzt, 2010
- Mitteilungen der DGPPN 6/08Der Nervenarzt, 2008
- Risperidone, haloperidol, and placebo in the treatment of aggressive challenging behaviour in patients with intellectual disability: a randomised controlled trialThe Lancet, 2008
- Psychotropic medication in adults with mental retardation: prevalence, and prescription practicesResearch in Developmental Disabilities, 2004
- Client Socio-Demographic and Service Receipt Inventory – European Version: development of an instrument for international researchThe British Journal of Psychiatry, 2000